International Journal of Pharma and Bio Sciences
    ISSN 0975-6299

Int J Pharm Bio Sci Volume 12 Issue 2, 2021 (April-June), Pages:54-59

Awareness of Breast cancer and current perspectives: An overview

Pooja G Singh, Kanthesh M Basalingappa, Gopenath Ts, Navya Raj Mp, Prathibha Rajashekara S and Sushma Bv.

Breast cancer is the most common diagnosed cancer form experienced in women and is second among women for the susceptibility of cancer fatality. Typically it is illness noticed among the individual of reproductive age in women. In the previous and current research data has shown a positive impact on improving the clinical outcome of breast cancer. It has become apparent in recent years that breast cancer is not a sign of single disease rather than a variety of molecular tumours from breast epithelial cells. This was due to the advances made in the control, inspection, diagnosis, and therapeutic strategies of breast cancer. Individualized therapeutic life style care often could improve the effectiveness of treatment and thereby lower rates of mortality. However, there is a significant inhibition effect and existing challenges noticed with respect to disease control, insufficient forecasts for Triple negative breast cancer (TNBC), and drug resistance. Cell lines tend to be a crucial element for molecular diagnostics in breast cancer, as they can be used extensively as in vitro models in cancer research in many areas of laboratory research and in particular. Breast cancer cells represent a very significant candidate, because they are used in various groups of ER-positive tumours with varying levels of nuclear receptor expression in research into estrogen receptor (ER)-positive breast cancer cell testing and several sub- clones which are identified. Likewise, the growing prevalence and mortality of breast cancer among the population in the developing world is a central concern. This review finding specially emphasises on current diagnostic screening technique, treatment strategies and potential limitations for breast cancer prognosis.

Keywords: Breast Cancer, molecular subtypes, tumor markers, metastasis, therapeutics.
Full HTML:


1.       International Agency for Research on Cancer, Global Cancer Observatory [cited 16.12.2020]. Available from:

2.       Bray F. The changing global burden of cancer: transitions in human development and implications for cancer prevention and control. 3rd ed. Available from: Vol. 3. Lyon: International Agency for Research on Cancer; 2014.

3.       Copeland et al. Cancer in north America: 2008-2012. Volume One: Combined Cancer Incidence for the United States, Canada and North America. Springfield: North American Publishing Association of Central Cancer Registries; 2015.

4.       Howlader et al. SEER Cancer statistics review, 1975-2012. Bethesda: National Cancer Institute; 2015. Available from:

5.       Palmer JR et al. Parity and lactation with estrogen receptor-negative breast cancer in African American women. Cancer Epidemiol Biomark Prev. 2011;20(9):1883-91. doi: 10.1158/1055-9965.EPI-11-0465.

6.       Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, Adams-Campbell LL, Prentice R. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005;97(6):439-48. doi: 10.1093/jnci/dji064, PMID 15770008.

7.       Ray M, Polite BN. Triple-negative breast cancers: a view from 10,000 feet. Cancer J. 2010;16(1):17-22. doi: 10.1097/PPO.0b013e3181d3eef5, PMID 20164686.

8.       Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol. 2009;169(10):1251-9. doi: 10.1093/aje/kwp036, PMID 19318616.

9.       Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9(1):R6. doi: 10.1186/bcr1639, PMID 17239243.

10.     Gukas ID, Girling AC, Mandong BM, Prime W, Jennings BA, Leinster SJ. A comparison of clinicopathological features and molecular markers in British and Nigerian women with breast cancer. Clin Med Oncol. 2008;2:347-51. doi: 10.4137/cmo.s474, PMID 21892296.

11.     Payne SJ, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer—the present. Histopathology. 2008;52(1):82-90. doi: 10.1111/j.1365-2559.2007.02897.x, PMID 18171419.

12.     Harris HR, Tamimi RM, Willett WC, Hankinson SE, Michels KB. Body size across the life course, mammographic density, and risk of breast cancer. Am J Epidemiol. 2011;174(8):909-18. doi: 10.1093/aje/kwr225, PMID 21911827.

13.     Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: current understanding and prospects. Breast Cancer Res. 2011;13(6):223. doi: 10.1186/bcr2942, PMID 22114898.

14.     Boyd NF, Melnichouk O, Martin LJ, Hislop G, Chiarelli AM, Yaffe MJ, Minkin S. Mammographic density, response to hormones, and breast cancer risk. J Clin Oncol. 2011;29(22):2985-92. doi: 10.1200/JCO.2010.33.7964, PMID 21709206.

15.     Maskarinec G, Pagano I, Lurie G, Kolonel LN. A longitudinal investigation of mammographic density: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2006;15(4):732-9. doi: 10.1158/1055-9965.EPI-05-0798, PMID 16614116.

16.     Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M. Genetic susceptibility to breast cancer. Mol Oncol. 2010;4(3):174-91. doi: 10.1016/j.molonc.2010.04.011, PMID 20542480.

17.     McPherson K, Steel CM, Dixon JM. Breast cancer—epidemiology, risk factors, and genetics. BMJ. 2000;321(7261):624-8. doi: 10.1136/bmj.321.7261.624, PMID 10977847.

18.     Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of breast carcinoma. Association of Directors of Anatomic and Surgical Pathology. Am J Clin Pathol. 1995;104(6):614-9. doi: 10.1093/ajcp/104.6.614, PMID 8526202.

19.     Malhotra GK, Zhao X, Band H, Band V. Histological, molecular, and functional subtypes of breast cancers. Cancer Biol Ther. 2010;10(10):955-60. doi: 10.4161/cbt.10.10.13879, PMID 21057215.

20.     Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005;93(9):1046-52. doi: 10.1038/sj.bjc.6602787, PMID 16175185.

21.     Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O’Malley FP, Page DL, Smith BL, Tan LK, Weaver DL, Winer E, Members of the Cancer. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med. 2009;133(10):1515-38. doi: 10.1043/1543-2165-133.10.1515, PMID 19792042.

22.     Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yankeelov T, National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2009;7(10):1060-96. doi: 10.6004/jnccn.2009.0070, PMID 19930975.

23.     Hon JD, Singh B, Sahin A, Du G, Wang J, Wang VY, Deng FM, Zhang DY, Monaco ME, Lee P. Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res. 2016;6(9):1864-72. PMID 27725895.

24.     Payne SJ, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer—the present. Histopathology. 2008;52(1):82-90. doi: 10.1111/j.1365-2559.2007.02897.x, PMID 18171419.

25.     Hashmi AA et al. Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters. BMC Res Notes. Available from: Vol. 2019; 2019. PMCID 6755684.

26.     Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P. Tumor markers in breast cancer –European Group on Tumor Markers Recommendations. Tumour Biol. 2005;26(6):281-93. doi: 10.1159/000089260, PMID 16254457.

27.     Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr, American Society of Clinical Oncology, American Society of Clinical Oncology. Update of recommendations for the use of tumor markers in the breast. J Clin Oncol. 2007;25(33):5287-312. doi: 10.1200/JCO.2007.14.2364, PMID 17954709.

28.     Pantel K, Alix-Panabières C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol. 2009;6(6):339-51. doi: 10.1038/nrclinonc.2009.44, PMID 19399023.

29.     Weber GF. Molecular mechanisms of metastasis. Cancer Lett. 2008;270(2):181-90. doi: 10.1016/j.canlet.2008.04.030, PMID 18522865.

30.     Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895-904. doi: 10.1038/nm1469, PMID 16892035.

31.     Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016;529(7586):298-306. doi: 10.1038/nature17038, PMID 26791720.

32.     Lin F, Wang N, Zhang TC. The role of endothelial-mesenchymal transition in development and pathological process. IUBMB Life. 2012;64(9):717-23. doi: 10.1002/iub.1059, PMID 22730243.

33.     Geay JF. Physiopathology, diagnosis, and treatment of breast cancer. Soins. 2013;776(776):25-9. PMID 23878881.

34.     NIH Consens Dev Conference on the treatment of early-stage breast cancer.Bethesda, Jun 18-21, 1990. J Natl Cancer Inst Monogr; 1992. p. 1-187.

35.     Fisher B, Mamounas EP. Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol. 1995;13(3):537-40. doi: 10.1200/JCO.1995.13.3.537, PMID 7884412.

36.     Aebi S, Gelber S, Lang I et al. Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: the CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG1-02). Cancer Res. 2012;72:96s. doi: 10.1158/0008-5472.CAN-12-0908.

37.     NIH Consens Dev Conference on the treatment of early-stage breast cancer. Bethesda, Jun 18-21, 1990. Available from: J Natl Cancer Inst Monogr; 1992. p. 1-187.

38.     Group EBCTC. Lancet. 1998;352(9132):930-42. PMID 9752815.

39.     Pegram MD, Konecny GE, O’Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004;96(10):739-49. doi: 10.1093/jnci/djh131, PMID 15150302.

40.     Killelea BK, Yang VQ, Mougalian S, Horowitz NR, Pusztai L, Chagpar AB, Lannin DR. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J Am Coll Surg. 2015;220(6):1063-9. doi: 10.1016/j.jamcollsurg.2015.02.011, PMID 25868410.

41.     O’Reil EA, Gubbins L, Sharma S, Tully R, Guang MH, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell M, McCann A. The fate of chemoresistance in triple-negative breast cancer (TNBC). BBA Clin. 2015;3:257-75. doi: 10.1016/j.bbacli.2015.03.003, PMID 26676166.

[Download PDF]
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy
Pharmaceutical Fields
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmaceutics
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Novel drug delivery system
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Nanotechnology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacognosy
© Copyright 2009-2015 IJPBS, India. All rights reserved. Specialized online journals by ubijournal. Website by Ubitech Solutions
         Home I Contact I Terms & Conditions